
Siyi He
Articles
-
Jun 25, 2024 |
virologyj.biomedcentral.com | Xinyan Yao |Kexin Xu |Nana Tao |Shengtao Cheng |Huajian Chen |Dapeng Zhang | +9 more
Correction: ZNF148 inhibits HBV replication by downregulating RXRα transcription Correction Open access Published: 25 June 2024 Virology Journal volume 21, Article number: 145 (2024) Cite this article The Original Article was published on 31 January 2024 Correction: Virology Journal (2024) 21:35Following publication of the original article [1], the authors identified an error in Fig. 1H.
-
Jan 31, 2024 |
virologyj.biomedcentral.com | Xinyan Yao |Kexin Xu |Nana Tao |Huajian Chen |Dapeng Zhang |Ming Tan | +9 more
HepAD38 and HepG2-NTCP cells were gifts from Xiamen University. HepAD38 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 400 mg/ml G418 (345,810, Merck Millipore, Germany). HepG2-NTCP cells were maintained in DMEM supplemented with 10% FBS and 2 μg/ml doxycycline (Dox; Solarbio, China). Huh7 cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China).
-
Dec 15, 2023 |
biorxiv.org | Siyi He |Luis Silva |Guy A. Rutter |Gareth Lim
AbstractInducing apoptosis in different types of cancer cells is an effective therapeutic strategy. However, the success of existing chemotherapeutics can be compromised by tumor cell resistance and systemic off-target effects. Therefore, the discovery of pro-apoptotic compounds with minimal systemic side-effects is crucial. 14-3-3 proteins are molecular scaffolds that serve as important regulators of cell survival.
-
Jun 9, 2023 |
pubmed.ncbi.nlm.nih.gov | Siyi He |Hong Qian |Xingbo Xu
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →